{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:55:14Z","timestamp":1785894914594,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04732-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:21:31Z","timestamp":1734628891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-4606","authenticated-orcid":false,"given":"Alice","family":"Matheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Collas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelle","family":"Grisard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Goulaieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00efla","family":"Bengrine-Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Goirand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"4732_CR1","unstructured":"Actualit\u00e9-Chimioth\u00e9rapies \u00e0 base de 5-FU ou cap\u00e9citabine\u202f: des pop-up pour alerter pharmaciens et m\u00e9decins sur l\u2019obligation d\u2019un d\u00e9pistage avant tout traitement-ANSM. https:\/\/ansm.sante.fr\/actualites\/chimiotherapies-a-base-de-5-fu-ou-capecitabine-des-pop-up-pour-alerter-pharmaciens-et-medecins-sur-lobligation-dun-depistage-avant-tout-traitement. Accessed 24 Mar 2023"},{"key":"4732_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338","journal-title":"Nat Rev Cancer"},{"key":"4732_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1081\/CBI-120002597","volume":"19","author":"G Milano","year":"2002","unstructured":"Milano G, Chamorey A-L (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177\u2013189","journal-title":"Chronobiol Int"},{"key":"4732_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3816\/CCC.2006.n.047","volume":"6","author":"C Mercier","year":"2006","unstructured":"Mercier C, Ciccolini J (2006) Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy. Clin Colorectal Cancer 6:288\u2013296","journal-title":"Clin Colorectal Cancer"},{"key":"4732_CR5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1515\/bchm.1997.378.9.1047","volume":"378","author":"AB Van Kuilenburg","year":"1997","unstructured":"Van Kuilenburg AB, Van Lenthe H, Wanders RJ et al (1997) Subcellular localization of dihydropyrimidine dehydrogenase. Biol Chem 378:1047\u20131053","journal-title":"Biol Chem"},{"key":"4732_CR6","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"EP L\u00e9vyPiedbois","year":"1998","unstructured":"Meta-Analysis Group In Cancer, L\u00e9vyPiedbois EP (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537\u20133541","journal-title":"J Clin Oncol"},{"key":"4732_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639\u20131650","journal-title":"Lancet Oncol"},{"key":"4732_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2015.65.1158","volume":"34","author":"WY Cheung","year":"2016","unstructured":"Cheung WY, Renfro LA, Kerr D et al (2016) Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the adjuvant colon cancer endpoints database. J Clin Oncol 34:1182\u20131189","journal-title":"J Clin Oncol"},{"key":"4732_CR9","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3390\/pharmaceutics14102119","volume":"14","author":"N Laures","year":"2022","unstructured":"Laures N, Konecki C, Brugel M et al (2022) Impact of guidelines regarding dihydropyrimidine dehydrogenase (DPD) deficiency screening using uracil-based phenotyping on the reduction of severe side effect of 5-fluorouracil-based chemotherapy: a propension score analysis. Pharmaceutics 14:2119","journal-title":"Pharmaceutics"},{"key":"4732_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"M-A Loriot","year":"2018","unstructured":"Loriot M-A, Ciccolini J, Thomas F et al (2018) Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-unicancer and RNPGx networks. Bull Cancer 105:397\u2013407","journal-title":"Bull Cancer"},{"key":"4732_CR11","unstructured":"M\u00e9thodes de recherche d\u2019un d\u00e9ficit en dihydropyrimidine deshydrog\u00e9nase visant \u00e0 pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res associ\u00e9es aux traitements incluant une fluoropyrimidine (5-fluorouracile ou cap\u00e9citabine). Haute Autorit\u00e9 de Sant\u00e9. https:\/\/www.has-sante.fr\/jcms\/c_2891090\/fr\/methodes-de-recherche-d-un-deficit-en-dihydropyrimidine-deshydrogenase-visant-a-prevenir-certaines-toxicites-severes-associees-aux-traitements-incluant-une-fluoropyrimidine-5-fluorouracile-ou-capecitabine. Accessed 13 Apr 2023"},{"key":"4732_CR12","unstructured":"EMA (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. European medicines agency. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Accessed 13 Apr 2023"},{"key":"4732_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cpt.2608","volume":"112","author":"M de With","year":"2022","unstructured":"de With M, Knikman J, de Man FM et al (2022) Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 112:62\u201368","journal-title":"Clin Pharmacol Ther"},{"key":"4732_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/bcp.15536","volume":"89","author":"M Maillard","year":"2023","unstructured":"Maillard M, Launay M, Royer B et al (2023) Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 89:762\u2013772","journal-title":"Br J Clin Pharmacol"},{"key":"4732_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","volume":"88","author":"C Gaible","year":"2021","unstructured":"Gaible C, Narjoz C, Loriot M-A et al (2021) Pretherapeutic screening for dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. Cancer Chemother Pharmacol 88:1049\u20131053","journal-title":"Cancer Chemother Pharmacol"},{"key":"4732_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.annonc.2022.04.073","volume":"33","author":"M Launay","year":"2022","unstructured":"Launay M, Guitton J, Balluet R et al (2022) Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference. Ann Oncol 33:850\u2013852","journal-title":"Ann Oncol"},{"key":"4732_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2015.10.013","volume":"54","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, van Hasselt JGC, Huitema ADR et al (2016) Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer 54:120\u2013130","journal-title":"Eur J Cancer"},{"key":"4732_CR18","doi-asserted-by":"publisher","first-page":"175883592211485","DOI":"10.1177\/17588359221148536","volume":"15","author":"S Callon","year":"2023","unstructured":"Callon S, Brugel M, Botsen D et al (2023) Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients. Ther Adv Med Oncol 15:17588359221148536","journal-title":"Ther Adv Med Oncol"},{"key":"4732_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117326","volume":"543","author":"C Narjoz","year":"2023","unstructured":"Narjoz C, Nadour Z, Zaanan A et al (2023) Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives. Clin Chim Acta 543:117326","journal-title":"Clin Chim Acta"},{"key":"4732_CR20","doi-asserted-by":"publisher","first-page":"11559","DOI":"10.18632\/oncotarget.24338","volume":"9","author":"K Morawska","year":"2018","unstructured":"Morawska K, Goirand F, Marceau L et al (2018) 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget 9:11559\u201311571","journal-title":"Oncotarget"},{"key":"4732_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"M-A Loriot","year":"2018","unstructured":"Loriot M-A, Ciccolini J, Thomas F et al (2018) D\u00e9pistage du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u202f: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx. Bull Cancer 105:397\u2013407","journal-title":"Bull Cancer"},{"key":"4732_CR22","first-page":"416","volume":"13","author":"M Dolat","year":"2020","unstructured":"Dolat M, Macaire P, Goirand F et al (2020) Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure. Pharm (Basel) 13:416","journal-title":"Pharm (Basel)"},{"key":"4732_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.dld.2020.11.004","volume":"53","author":"C Tron","year":"2021","unstructured":"Tron C, Lemaitre F, Boisteau E et al (2021) When helping the minority of patients may hurt the majority: the case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring. Dig Liver Dis 53:258\u2013260","journal-title":"Dig Liver Dis"},{"key":"4732_CR24","unstructured":"Meeting highlights from the pharmacovigilance risk assessment committee (PRAC) 2\u20135 September 2024 | European medicines agency (EMA). https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-september-2024. 2024, Accessed 26 Sept 2024"},{"key":"4732_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/jco.2013.31.4_suppl.428","volume":"31","author":"K Makihara","year":"2013","unstructured":"Makihara K, Mishima H, Azuma S et al (2013) Plasma concentrations of 5-FU and creatinine clearance as predictive markers for severe toxicities of capecitabine in patients with colorectal cancer. JCO 31:428\u2013428","journal-title":"JCO"},{"key":"4732_CR26","unstructured":"Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. https:\/\/journal.nzma.org.nz\/journal-articles\/testing-for-dihydropyrimidine-dehydrogenase-deficiency-in-new-zealand-to-improve-the-safe-use-of-5-fluorouracil-and-capecitabine-in-cancer-patients. Accessed 13 Jan 2024"},{"key":"4732_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","volume":"13","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol 13:566\u2013575","journal-title":"Ann Oncol"},{"key":"4732_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","volume":"49","author":"C Poole","year":"2002","unstructured":"Poole C, Gardiner J, Twelves C et al (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225\u2013234","journal-title":"Cancer Chemother Pharmacol"},{"key":"4732_CR29","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/annonc\/mdg302","volume":"14","author":"GF Fleming","year":"2003","unstructured":"Fleming GF, Schilsky RL, Schumm LP et al (2003) Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol 14:1142\u20131147","journal-title":"Ann Oncol"},{"key":"4732_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2125.2005.02472.x","volume":"60","author":"S Ito","year":"2005","unstructured":"Ito S, Kawamura T, Inada M et al (2005) Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using 13C-uracil as an in vivo probe. Br J Clin Pharmacol 60:584\u2013593","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04732-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04732-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04732-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:03:47Z","timestamp":1734631427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04732-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04732-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}